Century Therapeutics, Inc. Payments of Financing Costs
Century Therapeutics, Inc. (IPSC) reported Payments of Financing Costs of $554.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2022-05-16
- Century Therapeutics, Inc. payments of financing costs for the quarter ending 2021-03-31 was $554.00K.
- Century Therapeutics, Inc. payments of financing costs for the quarter ending 2020-12-31 was $0.00.
- Century Therapeutics, Inc. payments of financing costs for the quarter ending 2020-09-30 was $133.00K.
- Century Therapeutics, Inc. payments of financing costs for fiscal 2020 was $144.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2021-03-31 | $554.00K 10-Q · filed 2022-05-16 | $554.00K derived: sum of 2 quarters · filed 2022-05-16 | $687.00K derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $133.00K derived: sum of 2 quarters · filed 2022-03-17 | $144.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $144.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $11.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |